These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34117682)

  • 1. Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic.
    Culpan M; Keser F; Acar HC; Otunctemur A; Kucuk EV; Erdem S; Ozer M; Sen UT; Degirmenci E; Ergul R; Atis RG; Yildirim A
    Int J Clin Pract; 2021 Sep; 75(9):e14490. PubMed ID: 34117682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    Vanneste M; van der Heij B; Christiaansen CE; Berendsen CL; Driessen EJM; Bruins HM
    World J Urol; 2023 Aug; 41(8):2173-2178. PubMed ID: 37328699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
    Schroeck FR; Lynch KE; Li Z; MacKenzie TA; Han DS; Seigne JD; Robertson DJ; Sirovich B; Goodney PP
    Cancer; 2019 Sep; 125(18):3147-3154. PubMed ID: 31120559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
    Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
    BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
    Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
    [No Abstract]   [Full Text] [Related]  

  • 13. [Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].
    Wang F; Qin CP; DU YQ; Liu SJ; Li Q; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):669-673. PubMed ID: 35950390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
    Ma J; Roumiguie M; Hayashi T; Kohada Y; Zlotta AR; Lévy S; Matsumoto T; Sano T; Black PC
    Eur Urol Focus; 2024 Jan; 10(1):189-196. PubMed ID: 37442722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
    Kim JS; Lee J; Nguyen TT; Choi SY
    Sci Rep; 2024 Apr; 14(1):8440. PubMed ID: 38600160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of local recurrences in the irradiated bladder: a systematic review.
    Sapre N; Anderson P; Foroudi F
    BJU Int; 2012 Dec; 110 Suppl 4():51-7. PubMed ID: 23194126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
    Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
    Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible cystoscopy and Holmium:Yttrium aluminum garnet laser ablation for recurrent nonmuscle invasive bladder carcinoma under local anesthesia.
    Syed HA; Talbot N; Abbas A; MacDonald D; Jones R; Marr TJ; Rukin NJ
    J Endourol; 2013 Jul; 27(7):886-91. PubMed ID: 23537221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.